$12.24
3.16% today
Nasdaq, Dec 04, 10:00 pm CET
ISIN
CA10778Y3023
Symbol
BCTX

BriaCell Therapeutics Corp Stock price

$12.24
+2.16 21.43% 1M
-20.66 62.80% 6M
-72.51 85.56% YTD
-143.76 92.15% 1Y
+6.43 110.67% 3Y
+8.46 223.81% 5Y
-39.96 76.55% 10Y
-366.06 96.76% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
-0.40 3.16%
ISIN
CA10778Y3023
Symbol
BCTX
Industry

Key metrics

Basic
Market capitalization
$18.7m
Enterprise Value
$690.0k
Net debt
positive
Cash
$18.0m
Shares outstanding
1.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 8.8
EV/Sales
- | 0.3
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
81.8%
Return on Equity
-146.2%
ROCE
-151.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $2.1m
EBITDA
$-27.1m | -
EBIT
$-27.2m | $-34.0m
Net Income
$-26.3m | $-21.7m
Free Cash Flow
$-28.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
18.5% | -
EBIT
18.4% | -25.1%
Net Income
-486.0% | 17.4%
Free Cash Flow
-15.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -1,025.1%
Free Cash Flow
-
More
EPS
$-30.0
FCF per Share
$-15.0
Short interest
6.1%
Employees
16
Rev per Employee
$0.0
Show more

Is BriaCell Therapeutics Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

BriaCell Therapeutics Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a BriaCell Therapeutics Corp forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a BriaCell Therapeutics Corp forecast:

Buy
80%
Hold
20%

Financial data from BriaCell Therapeutics Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.94 5.94
3% 3%
-
- Research and Development Expense 21 21
22% 22%
-
-27 -27
19% 19%
-
- Depreciation and Amortization 0.11 0.11
22% 22%
-
EBIT (Operating Income) EBIT -27 -27
18% 18%
-
Net Profit -26 -26
486% 486%
-

In millions USD.

Don't miss a Thing! We will send you all news about BriaCell Therapeutics Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BriaCell Therapeutics Corp Stock News

Neutral
GlobeNewsWire
2 days ago
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will be presenting positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio ...
Neutral
GlobeNewsWire
9 days ago
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium...
Neutral
GlobeNewsWire
14 days ago
PHILADELPHIA and VANCOUVER, British Columbia and BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, has announces that its subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), has initiated a research collab...
More BriaCell Therapeutics Corp News

Company Profile

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Head office Canada
CEO William Williams
Employees 16
Founded 2006
Website briacell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today